3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
8
Meningioma
2
Glioblastoma
2
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Medulloblastoma
1
Glioma
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Disease Progression
1
Carcinoid Tumor
1
Advanced Lung Neuroendocrine Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Adenoma, Islet Cell
1
Interventions
olaparib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
tipifarnib
1
lutetium Lu 177 dotatate
1
fluorodopa F 18
1
belzutifan
1
Temozolomide
1
Nivolumab
1
Ipilimumab
1
Fluorodeoxyglucose F18
1
Contrast Media
1
CTLA-4 Antigen
1
6-fluorodopamine
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
lutetium Lu 177 dotatate
×
30 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled